Form 4: Actuate Therapeutics Director Amy L. Ronneberg Granted 15,000 Stock Options

Actuate Therapeutics, Inc. Director Amy L. Ronneberg was granted 15,000 stock options with an exercise price of $10.10, as disclosed in a recent SEC Form 4 filing.

Summary

• Amy L. Ronneberg, a Director of Actuate Therapeutics, Inc. (ACTU), was granted 15,000 stock options.
• The transaction date for this grant was May 22, 2025.
• The exercise price for these stock options is $10.10 per share.
• The options are for Common Stock, with 15,000 shares underlying the derivative security.
• These options will vest in full on the anniversary of the grant date.
• The expiration date for these stock options is May 22, 2035.
• Following this transaction, Amy L. Ronneberg beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. However, it's a routine compensation event, not a significant operational or financial announcement.

Positives

• The grant of stock options to Director Amy L. Ronneberg aligns her interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date (May 22, 2035), providing a long-term incentive horizon.

Future Outlook

This filing pertains to an insider compensation event and does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction.

Industry Context

This SEC Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director. Such grants are common practice across industries to align management and board interests with shareholder value creation.

Related Party Transactions

• Grant of 15,000 stock options to Amy L. Ronneberg, a Director of Actuate Therapeutics, Inc., as part of her compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted stock options will vest in full on the anniversary of the grant date (May 22, 2026).

Key Dates

Keywords

Actuate Therapeutics, ACTU, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership